EP 1554281 A4 20090225 - PROCESS FOR PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS
Title (en)
PROCESS FOR PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS
Title (de)
VERFAHREN ZUR HERSTELLUNG BESTIMMTER PYRROLOTRIAZINVERBINDUNGEN
Title (fr)
PROCEDE DE PREPARATION DE CERTAINS COMPOSES DE PYRROLOTRIAZINE
Publication
Application
Priority
- US 0322755 W 20030721
- US 39725602 P 20020719
- US 44721303 P 20030213
- US 62228003 A 20030718
Abstract (en)
[origin: WO2004009542A2] The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
IPC 1-7
IPC 8 full level
A61K 31/53 (2006.01); A61K 45/06 (2006.01); A61P 13/08 (2006.01); A61P 29/00 (2006.01); A61P 37/00 (2006.01); C07D 487/04 (2006.01)
CPC (source: EP US)
A61K 31/53 (2013.01 - EP US); A61K 45/06 (2013.01 - EP US); A61P 1/04 (2017.12 - EP); A61P 1/16 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 7/00 (2017.12 - EP); A61P 7/04 (2017.12 - EP); A61P 7/06 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/06 (2017.12 - EP); A61P 9/08 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 13/08 (2017.12 - EP); A61P 13/10 (2017.12 - EP); A61P 13/12 (2017.12 - EP); A61P 15/00 (2017.12 - EP); A61P 17/02 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 21/04 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/02 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 27/16 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 31/10 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 31/18 (2017.12 - EP); A61P 31/22 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 35/02 (2017.12 - EP); A61P 35/04 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/02 (2017.12 - EP); A61P 37/04 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 487/04 (2013.01 - EP US)
Citation (search report)
- [AD] WO 0071129 A1 20001130 - BRISTOL MYERS SQUIBB CO [US]
- [A] WO 0212227 A2 20020214 - ASTRAZENECA AB [SE], et al
- See references of WO 2004009542A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated extension state (EPC)
AL LT LV MK
DOCDB simple family (publication)
WO 2004009542 A2 20040129; WO 2004009542 A3 20040513; AU 2003256645 A1 20040209; BR 0312648 A 20050802; CA 2492861 A1 20040129; CN 1665817 A 20050907; EP 1554281 A2 20050720; EP 1554281 A4 20090225; IL 165985 A0 20060115; JP 2006502120 A 20060119; MX PA05000344 A 20050331; PL 375316 A1 20051128; TW 200409776 A 20040616; TW I272271 B 20070201; US 2004077858 A1 20040422; US 6933386 B2 20050823
DOCDB simple family (application)
US 0322755 W 20030721; AU 2003256645 A 20030721; BR 0312648 A 20030721; CA 2492861 A 20030721; CN 03816201 A 20030721; EP 03765846 A 20030721; IL 16598503 A 20030721; JP 2004523221 A 20030721; MX PA05000344 A 20030721; PL 37531603 A 20030721; TW 92119890 A 20030718; US 62228003 A 20030718